Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis

Not Applicable

Not yet recruiting

• Conditions: Idiopathic Pulmonary Fibrosis (IPF)
• Interventions: Biological: SC01009 injection; Biological: Placebo Group(Vehicle)

• Registration Number: NCT07131150
• Lead Sponsor: Ruijin Hospital

Brief Summary

At present, the diagnosis of IPF is still difficult and it cannot be completely cured. Treatment is still aimed at improving symptoms and delaying the decline of lung function. The treatment measures for IPF mainly include drug therapy ( pirfenidone and nintedanib), non-drug therapy (such as oxygen therapy, pulmonary rehabilitation), treatment of complications/comorbidities, symptomatic treatment and palliative treatment. However, IPF cannot be completely cured at present, so lung transplantation is a feasible option for the treatment of IPF. However, due to the scarcity of donor lungs, prevention of acute and chronic rejection reactions, post-transplant infection complications, and high costs, its clinical implementation is limited. Therefore, there is still a large unmet treatment need for IPF, and new therapeutic drugs are urgently needed.

In recent years, mesenchymal stem cells (MSCs) have been considered a new hope for the treatment of IPF. MSCs are a type of multipotent stem cells with the potential for self-proliferation and differentiation. They have the characteristics of self-renewal, multidirectional differentiation, low immunogenicity, and paracrine. They can automatically home to damaged areas, promote epithelial tissue repair, inhibit inflammation, and inhibit abnormal proliferation of fibroblasts . Many clinical trials at home and abroad are exploring the effectiveness and safety of MSC in the treatment of pulmonary fibrosis. An Australian study found that in patients with moderate to severe IPF, intravenous infusion of umbilical cord MSCs up to 2 × 106 cells/kg was safe, and no decrease in forced vital capacity (FVC), diffusing vital capacity for carbon monoxide (DLCO), 6-minute walk test distance (6MWD), and CT fibrosis score was observed during a 6-month follow-up . The results of the American AETHER study also showed that a single intravenous infusion of up to 2 × 10\^ 8 cells of bone marrow MSCs was safe, with no serious treatment-related adverse events observed. Moreover, 60 weeks after infusion , FVC% decreased by 3.0% and DLCO% decreased by 5.4%, both of which were below the threshold for disease progression .

This study adopted a multicenter, randomized, double-blind, placebo-controlled, parallel design to evaluate the efficacy and safety of SC01009 injection in IPF subjects .

This study plans to enroll 66 subjects, who will be randomly stratified according to whether they have received oral pirfenidone/nintedanib treatment at screening , and randomly assigned to two trial groups and one placebo group in a 1:1:1 ratio.

This study includes a screening period of up to 4 weeks, a 24-week treatment follow-up period, and a 2-year long-term follow-up period. After screening, qualified subjects will be given medication according to the following dosing schedule according to their group:

Trial Group 1: received intravenous infusion of SC01009 injection in week 1, divided into 3 infusions every other day, each infusion of 3 × 10\^ 7 cells, with a total dose of 9 × 10 \^7 cells; received intravenous infusion of placebo in week 13, with the same administration method as in week 1; Experimental group 2: received intravenous infusion of SC01009 injection at week 1 and week 13, respectively. Each administration was divided into 3 infusions every other day, with 3 × 10\^7 cells in each infusion , and the total dose was 1.8 × 10\^8 cells.

Placebo group: received intravenous infusion of placebo at week 1 and week 13, respectively, with the same administration method as the cell therapy group.

After completing 24 weeks of treatment follow-up, all subjects entered the long-term follow-up phase and were unblinded after the study database was locked . The subjects in the original placebo group could end the follow-up, while the subjects receiving cell therapy would continue to be followed up for up to 2 years.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2025-07-14
• Status Verified: 2025-08
• Study First Submitted QC: 2025-08-19
• Last Update Submitted: 2025-08-19
• Study First Posted: 2025-08-20
• Last Update Posted: 2025-08-20
• Study Start: 2025-08-31
• Primary Completion: 2028-07-31
• Study Completion: 2028-07-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

• 1. Voluntarily sign the written informed consent (ICF) and agree to complete the trial according to the protocol requirements;
• 2. ≥ 18 and ≤ 80 years old when signing the ICF , regardless of gender;
• 3. Diagnostic Confirmation of IPF;
• 4. ≥ 50% and ≤ 90% at screening ; DLCO% ≥ 30% and ≤ 90% (corrected for hemoglobin [Hb]);
• 5. received nintedanib or pirfenidone treatment for at least 8 weeks before screening and do not plan to start or restart anti-fibrotic treatment; or patients who have received stable nintedanib or pirfenidone treatment for at least 8 weeks before screening and do not receive combination therapy of nintedanib and pirfenidone ;
• 6. 2 ≥ 60 mmHg at screening ; able to complete the 6- minute walk test ( 6MWT ) and walk distance > 150 m;
• 7. are willing to use at least one effective contraceptive method for contraception during the study .

Exclusion Criteria

• 1. Other lung diseases within 6 months before screening, including chronic obstructive pulmonary disease (forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) after using bronchodilator < 0.70), emphysema (emphysema occupies ≥ 50% of the entire HRCT according to the central review of HRCT, or the degree of emphysema is greater than the degree of fibrosis), pulmonary hypertension ≥ 50 mmHg indicated by echocardiography , active tuberculosis, pulmonary embolism, uncontrolled asthma, pneumothorax, pneumoconiosis, bronchiolitis obliterans or other active lung diseases;
• 2. In addition to IPF, there are other types of interstitial lung disease (ILD), including ILD with known causes (such as family or occupational environmental exposure, connective tissue disease and drug toxicity, etc.), granulomatous ILD (such as sarcoidosis), and other rare ILD (such as alveolar proteinosis, pulmonary amyloidosis, etc.); among them, for the exclusion of connective tissue disease-related interstitial lung disease ( CTD-ILD), relevant examinations within 12 months before screening were accepted;
• 3. Patients who are in the acute exacerbation stage of IPF at the time of screening, or who have AE-IPF within 3 months before screening (determined by the investigator); AE-IPF is defined as: IPF patients who have a significant acute deterioration of respiratory function in a short period of time, mainly characterized by the new appearance of diffuse ground-glass shadows and/or consolidation shadows in both lungs on the original UIP background on chest HRCT;
• 4. Patients with lung infection or other serious infection requiring intravenous antibiotic treatment within 4 weeks before screening;
• 5. Patients with a history or evidence of major cardiovascular disease within 6 months before screening, including but not limited to: myocardial infarction, coronary angioplasty or bypass surgery, heart valve repair, II or III degree atrioventricular block, malignant arrhythmia ( such as ventricular tachycardia, frequent supraventricular tachycardia, atrial fibrillation, atrial flutter, etc. ), unstable angina, transient ischemic attack, cerebrovascular accident, congestive heart failure with a heart function grade of III or IV of the New York Heart Association (NYHA) , etc.; or left ventricular ejection fraction (LVEF) <50% at screening;
• 6. Patients with a history of tumor (except for patients with cured basal cell carcinoma of the skin, squamous cell carcinoma in situ of the skin, or carcinoma in situ of the cervix), or patients whose tumor marker examinations are determined by the investigator to be clinically significant and may affect safety assessments;
• 7. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × upper limit of normal (ULN), or total bilirubin (TBIL) >1.5 × ULN at screening;
• 8. Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73m² at screening;
• 9. Patients who are positive for hepatitis B surface antigen (HBsAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) ≥ the lower limit of the detection value during screening, or who are positive for hepatitis C virus (HCV) antibody and hepatitis C virus ribonucleic acid (HCV-RNA) ≥ the lower limit of the detection value, or who are positive for human immunodeficiency virus (HIV) antibody, or who are positive for Treponema pallidum antibody (Those who are positive for Treponema pallidum antibody need to undergo non-specific syphilis antibody test and the researchers will determine whether they can participate in the trial);
• 10. Blood pressure is still not controlled after antihypertensive drug treatment within 3 months before screening, and blood pressure during the screening period is ≥ 160/100 mmHg;
• 11. Patients planning to receive lung transplantation or with a history of solid organ transplantation;
• 12. Those who have undergone lung resection; or those who have undergone major surgery (including lung surgery) or unhealed wounds (except for diagnostic surgery or when the investigator determines that the subject has fully recovered from the surgery) within 4 weeks before screening, or those who are planning to undergo major surgery;
• 13. 20 mg/ d (or other glucocorticoids of equivalent dose) within 28 days before screening ;
• 14. Use of cytotoxic drugs (such as chloramphenicol, azathioprine , cyclophosphamide, methotrexate ) or pulmonary hypertension drugs (such as endothelin receptor antagonists [such as bosentan, ambrisentan, macitentan], PDE5 inhibitors [such as sildenafil, tadalafil, vardenafil ]) within 4 weeks or 5 half -lives before screening (whichever is longer) ;
• 15. Use of drugs that may cause pulmonary fibrosis within 6 months before screening, such as amiodarone, bleomycin, etc.;
• 16. Patients who are known or suspected to be allergic to the active or inactive ingredients of the investigational drug (such as dimethyl sulfoxide [DMSO], human serum albumin [HSA], dextran, and compound electrolytes) ;
• 17. Those with a history of drug abuse or other serious mental illness, who may increase the risk of participating in the study or interfere with the study treatment and research results as determined by the researchers;
• 18. Participants who have participated in any other clinical trials within 3 months before screening (except patients who have not received trial drugs); or participated in mesenchymal stem cell clinical trials within 2 years before screening; or received other types of stem cells before screening;
• 19. Other situations that the researcher considers unsuitable for participation in this trial.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Trial Group 1	SC01009 injection	-
Placebo Group	Placebo Group(Vehicle)	-
Trial Group2	SC01009 injection	-

Primary Outcome Measures

Name	Time	Method
Change from baseline in forced vital capacity (FVC) (ml)	Baseline, Week 24

Secondary Outcome Measures

Name	Time	Method
Changes from baseline in forced vital capacity % predicted (FVC%)	weeks 4, 12, and 24 ;
arterial oxygen partial pressure (PaO 2 ) from baseline	weeks 4 , 12 , and 24
Changes from baseline in the diffusing capacity for carbon monoxide as a percentage of predicted value (DLCO%)	baseline, week 24
a. FVC (ml) decreased by ≥ 10% or DLCO% decreased by ≥ 15% compared with baseline; b. Acute exacerbation of IPF (AE-IPF); c. All-cause mortality occurred;	Time to first clinical worsening event, including any of the following
Changes in FVC (ml) from baseline	weeks 4 and 12
Changes in DLCO% from baseline	weeks 4 and 12
Changes from baseline in 6-minute walk test distance (6MWD)	weeks 4, 12, and 24;
Number of Participants with Post-Treatment Abnormalities in Vital Signs	Baseline，Day 1 ，up to 24 weeks	Number of Participants with Post-Treatment Abnormalities in Vital Signs as Assessed by CTCAE v5.0
Number of Participants with post-treatment normality/abnormality transitions	Baseline，Day 1 ，up to 24 weeks	Number of Participants with post-treatment normality/abnormality transitions (Normal, Abnormal - Not Clinically Significant, Abnormal - Clinically Significant)
12- lead electrocardiogram ( ECG ) examination	Baseline，Day 1， up to 24 weeks	including heart rate (HR), PR interval , QT interval, RR interval, QTcF and QRS complex duration，Clinical assessment outcomes (Normal, Abnormal - Not Clinically Significant, Abnormal - Clinically Significant) with pre-/post-treatment normality/abnormality transitions
Occurrence of Infusion Reactions	during administration and within 8 hours after completion of administration
Changes from baseline in the Instructions for Completing the Living with Pulmonary Fibrosis Impacts Questionnaire (L-PF Impacts) and Instructions for Completing the Living with Pulmonary Fibrosis Symptoms Questionnaire (L-PF Symptoms)	weeks 4, 12, and 24	Score range: 0 to 92, higher scores mean a worse outcome
The occurrence of adverse events (AEs)/serious adverse events (SAEs)	Baseline，Day 1 ，up to 24 weeks，2years	Number of participants with treatment-related adverse events as assessed by CTCAE 5.0，Tumorigenicity assessment during the 2-year observation period following the main observation period
Number of Participants with Post-Treatment Abnormalities in Laboratory tests	Baseline，Day 1， up to 24 weeks	Number of Participants with Post-Treatment Abnormalities in Laboratory tests (Complete Blood Count, Blood Biochemistry, Urinalysis, Coagulation Function, C-reactive Protein \[CRP\]) as Assessed by CTCAE v5.0

Trial Locations

Locations (22)

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; 🇨🇳 Beijing, Beijing, China

Beijing Chaoyang Hospital Affiliated to Capital Medical University; 🇨🇳 Beijing, Beijing, China

China-Japan Friendship Hospital; 🇨🇳 Beijing, Beijing, China

Beijing FriendBeijing Friendship Hospital, Capital Medical UniversityBeijing Friendship Hospital, Capital Medical Universityship Hospital, Capital Medical University; 🇨🇳 Beijing, Beijing, China

The Fifth Medical Center of PLA General Hospital; 🇨🇳 Beijing, Beijing, China

The First Affiliated Hospital of Guangzhou Medical University; 🇨🇳 Guangzhou, Guangdong, China

Shenzhen People's Hospital; 🇨🇳 Shenzhen, Guangdong, China

The Second Hospital of Hebei Medical University; 🇨🇳 Hebei, Hebei, China

Henan Provincial People's Hospital; 🇨🇳 Zhengzhou, Henan, China

Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology; 🇨🇳 Wuhan, Hubei, China

Scroll for more (12 remaining)